

HEALTHWAY MEDICAL CORPORATION LIMITED

(Registration No.: 200708625C)

(Incorporated in the Republic of Singapore)

(the “**Company**”)

UPDATE IN RELATION TO THE INDEPENDENT REVIEW

The Board of Directors (“**Board**” or “**Directors**”) of the Company refers to the announcements of the Company made on 27 February 2017, 11 April 2017 and 8 December 2017 (collectively, the “**Announcements**”) in relation to the appointment of BDO LLP as independent reviewer to look into the extensions of loans by the Company and its subsidiaries to Healthway Medical Enterprises Pte. Ltd. and Wei Yi Shi Ye Co. Ltd., with the objective of establishing whether there were any breaches of the SGX-ST Listing Manual Section B: Rules of Catalist (the “**Independent Review**”).

Further to the Announcements, the Company wishes to inform shareholders that, BDO LLP has substantially completed its review and is working towards finalising their Independent Review report. As more time is required to finalise the Independent Review report, barring any unforeseen circumstances, the Company expects the Independent Review report to be finalised in the second quarter of 2018. The Company will update shareholders as and when there are material updates in relation to the Independent Review, including the key findings of BDO LLP.

In the meantime, the Board wishes to advise shareholders of the Company and investors to exercise caution when dealing in the shares of the Company (“**Shares**”) and to refrain from taking any action in relation to their Shares which may be prejudicial to their interests. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors, accountants, tax advisers or other professional advisers immediately.

BY ORDER OF THE BOARD

Raymond Lam Kuo Wei
Company Secretary

28 March 2018

*This announcement has been prepared by Healthway Medical Corporation Limited (the “**Company**”) and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”), for compliance with the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGXST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).